Market Cap
US$13.1b
Last Updated
2019/11/20 23:36 UTC
Data Sources
Company Financials +
Executive Summary
Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally.
Snowflake
Adequate balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Hologic's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HOLX has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
4.9%
HOLX
1.8%
US Medical Equipment
0.5%
US Market
1 Year Return
18.4%
HOLX
23.3%
US Medical Equipment
16.1%
US Market
Return vs Industry: HOLX underperformed the US Medical Equipment industry which returned 23.3% over the past year.
Return vs Market: HOLX exceeded the US Market which returned 16.1% over the past year.
Shareholder returns
| HOLX | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.9% | 1.8% | 0.5% |
| 30 Day | 0.02% | 4.3% | 3.9% |
| 90 Day | -1.3% | 2.8% | 6.6% |
| 1 Year | 18.4%18.4% | 24.3%23.3% | 18.7%16.1% |
| 3 Year | 26.2%26.2% | 88.6%82.9% | 47.2%37.7% |
| 5 Year | 85.8%85.8% | 116.3%92.9% | 61.5%43.7% |
Price Volatility Vs. Market
How volatile is Hologic's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Hologic, Inc. Just Released Its Annual And Analysts Have Been Updating Their Estimates2 weeks ago | Simply Wall St
These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well1 month ago | Simply Wall St
Need To Know: Hologic, Inc. (NASDAQ:HOLX) Insiders Have Been Selling SharesValuation
Is Hologic undervalued compared to its fair value and its price relative to the market?
22.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HOLX ($49.19) is trading below our estimate of fair value ($63.55)
Significantly Below Fair Value: HOLX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: HOLX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: HOLX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HOLX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HOLX is overvalued based on its PB Ratio (5.8x) compared to the US Medical Equipment industry average (3.8x).
Next Steps
Future Growth
How is Hologic forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
55.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HOLX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: HOLX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HOLX's is expected to become profitable in the next 3 years.
Revenue vs Market: HOLX's revenue (3.3% per year) is forecast to grow slower than the US market (7.3% per year).
High Growth Revenue: HOLX's revenue (3.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HOLX's Return on Equity is forecast to be high in 3 years time (21.7%)
Next Steps
Past Performance
How has Hologic performed over the past 5 years?
-12.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HOLX has large one-off items impacting its financial results.
Growing Profit Margin: HOLX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HOLX is unprofitable, and losses have increased over the past 5 years at a rate of -12% per year.
Accelerating Growth: Unable to compare HOLX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HOLX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.3%).
Return on Equity
High ROE: HOLX has a negative Return on Equity (-1.76%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Hologic's financial position?
Financial Position Analysis
Short Term Liabilities: HOLX's short term assets ($1.8B) exceeds its short term liabilities ($1.1B)
Long Term Liabilities: HOLX's short term assets ($1.8B) do not cover its long term liabilities (3.3B)
Debt to Equity History and Analysis
Debt Level: HOLX's debt to equity ratio (133.1%) is considered high.
Reducing Debt: HOLX's debt to equity ratio has reduced from 206.4% to 133.1% over the past 5 years.
Balance Sheet
Inventory Level: HOLX has a low level of unsold assets or inventory.
Debt Coverage by Assets: HOLX's debt is not covered by short term assets (assets are 0.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable HOLX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: HOLX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 26.3% per year.
Next Steps
Dividend
What is Hologic's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate HOLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate HOLX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HOLX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HOLX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HOLX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Hologic's salary, the management and board of directors tenure and is there insider trading?
4.8yrs
Average management tenure
CEO
Steve MacMillan (55yo)
5.9yrs
Tenure
US$42,040,142
Compensation
Mr. Stephen P. MacMillan, also known as Steve, has been the Chairman of the Board at Hologic Inc. since June 17, 2015 and its Chief Executive Officer and President since December 9, 2013. Mr. MacMillan ser ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD42.04M) is above average for companies of similar size in the US market ($USD11.01M).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
4.8yrs
Average Tenure
55.5yo
Average Age
Experienced Management: HOLX's management team is considered experienced (4.8 years average tenure).
Board Age and Tenure
2.9yrs
Average Tenure
58yo
Average Age
Experienced Board: HOLX's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Unit President Division President of Breast & Skeletal Health Solutions |
| Shares | 4,242 |
| Max Price | US$47.38 |
| Entity | Individual |
| Role | Unit President Division President of Breast & Skeletal Health Solutions |
| Shares | 4,740 |
| Max Price | US$42.20 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Jay Stein (76yo)
Co-Founder
- Tenure: 12.1yrs
- Compensation: US$1.59m
Steve MacMillan (55yo)
Chairman
- Tenure: 5.9yrs
- Compensation: US$42.04m
Karleen Oberton (49yo)
Chief Financial Officer
- Tenure: 1.3yrs
- Compensation: US$3.02m
Michael Watts
Vice President of Investor Relations & Corporate Communications
- Tenure: 0yrs
Pete Valenti (56yo)
Division President of Breast & Skeletal Health Solutions
- Tenure: 5.5yrs
- Compensation: US$2.04m
John Griffin (58yo)
General Counsel
- Tenure: 4.8yrs
- Compensation: US$2.43m
Ali Bebo (50yo)
Senior Vice President of Human Resources
- Tenure: 4.8yrs
Jan Verstreken
Regional President for Europe
- Tenure: 0yrs
Sanjay Prabhakaran
Regional President of Asia Pacific
- Tenure: 0yrs
Monica Berthelot
Chief of Staff
- Tenure: 0.8yrs
Board Members
Jay Stein (76yo)
Co-Founder
- Tenure: 12.1yrs
- Compensation: US$1.59m
Steve MacMillan (55yo)
Chairman
- Tenure: 5.9yrs
- Compensation: US$42.04m
Scott Garrett (69yo)
Independent Director
- Tenure: 6.5yrs
- Compensation: US$278.49k
Sally Crawford (65yo)
Lead Independent Director
- Tenure: 2.8yrs
- Compensation: US$357.68k
Ludwig Hantson (56yo)
Independent Director
- Tenure: 1yrs
Charles Dockendorff (65yo)
Independent Director
- Tenure: 2.5yrs
- Compensation: US$273.99k
Christiana Stamoulis (48yo)
Independent Director
- Tenure: 8yrs
- Compensation: US$266.49k
Namal Nawana (48yo)
Independent Director
- Tenure: 1.8yrs
- Compensation: US$264.94k
Amy Wendell (58yo)
Independent Director
- Tenure: 2.9yrs
- Compensation: US$266.49k
Company Information
Hologic, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Hologic, Inc.
- Ticker: HOLX
- Exchange: NasdaqGS
- Founded: 1985
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$13.149b
- Shares outstanding: 267.31m
- Website: https://www.hologic.com
Number of Employees
Location
- Hologic, Inc.
- 250 Campus Drive
- Marlborough
- Massachusetts
- 1752
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| HOLX | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Mar 1990 |
| HO1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Mar 1990 |
| HOLX | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Mar 1990 |
| 0J5Q | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Mar 1990 |
| HOLX * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Mar 1990 |
Biography
Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacif ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/20 23:36 |
| End of Day Share Price | 2019/11/20 00:00 |
| Earnings | 2019/09/28 |
| Annual Earnings | 2019/09/28 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.